Direct Genomic Transformation for Breakthrough Research and Therapeutic Intervention. In vivo gene editing represents the cutting edge of genetic engineering, enabling the precise modification of DNA directly within the living organism. By bypassing the need for cell isolation and re-infusion, this approach allows for the systemic or site-specific alteration of genetic sequences in their natural physiological context. CD Biosynsis offers a comprehensive In Vivo Gene Editing Service, providing a robust platform that integrates advanced delivery vehicles with high-fidelity editing tools to accelerate functional genomics and therapeutic development.
Get a Technical QuoteOur in vivo platform provides end-to-end solutions for direct genomic modification, optimized for safety, tissue-specific targeting, and high editing efficiency across various species. We offer multiple delivery and editing modalities to suit specific research goals.
| Service Tier | Technical Focus | Primary Application | Industrial/Research Value |
|---|---|---|---|
| Tissue-Specific KO/KI | Targeted viral/non-viral delivery | Neuroscience & Organ-specific study | Maps gene function in adult organisms |
| Therapeutic Target Validation | Systemic or local gene disruption | Rare disease & Oncology R&D | Validates drug targets in vivo |
| Epigenome Modulation | CRISPRi/CRISPRa (non-cleaving) | Metabolic & Neurological disorders | Regulates expression without DNA breaks |
| Humanized In Vivo Models | Species-specific sequence swap | Pre-clinical efficacy testing | Mimics human disease states in animal hosts |
| Agricultural In Planta Editing | Germline/Somatic direct delivery | Crop resilience & Yield enhancement | Rapidly introduces traits into mature plants |
1. Vector Design
2. Production & QC
3. Direct Administration
4. Phenotypic Validation
Selection of genomic targets and design of viral or non-viral vectors tailored for specific tissues and species.
Detailed feasibility assessment and Mutual NDA signing.
High-titer production of AAV, Lentivirus, or LNP-encapsulated payloads under stringent purity standards.
Rigorous quality control to ensure optimal cargo stability and delivery efficiency.
Execution of in vivo delivery via systemic injection or localized administration (e.g., stereotactic or intraparenchymal).
Professional handling and precise dosing to maximize therapeutic window and safety.
Longitudinal monitoring followed by post-study molecular analysis (NGS, Western Blot) and physiological assays.
Final delivery of comprehensive data dossiers and genetic performance metrics.
To deliver world-class results, our technical team monitors and benchmarks our protocols against landmark research.
Researching genetic drivers of complex behavior requires precise control. Benchmarks have demonstrated the use of AAV to deliver CRISPR/Cas9 to the amygdala of non-human primates. By knocking out receptors (e.g., CB1R) in adult monkeys, researchers can observe immediate behavioral impacts, bypassing compensations found in traditional embryonic models.
(Reference: In vivo gene editing in adult macaques)
In vivo gene editing offers a potential one-time cure for hereditary conditions. Advanced studies utilized AAV vectors to deliver CRISPR/Cas9 for the in vivo knockout of the TTR gene in Transthyretin Amyloidosis (ATTR) models. By reducing pathogenic protein expression at the source, this technology eliminates chronic drug dependency.
(Reference: TTR Gene Editing for ATTR Treatment, 2021)
In the agricultural sector, in vivo delivery provides a faster route to resilience. Researchers have successfully utilized in planta CRISPR/Cas9 delivery to perform gene knockouts in wheat. This approach enhanced resistance to fungal pathogens like rust, rapidly introducing genetic changes that improve yield and stress tolerance.
(Reference: CRISPR-mediated disease resistance in wheat)
Ready to leverage direct genomic modification for your research?
Contact Us1. How do you ensure editing is limited to a specific organ?
We use a dual-targeting strategy: selecting a delivery vehicle with natural tropism for the organ and incorporating tissue-specific promoters that only activate in target cells.
2. What is the risk of off-target effects in a living organism?
We minimize this risk by using high-fidelity nucleases and computationally optimized gRNAs. We also utilize "self-inactivating" vectors where appropriate.
3. Is In Vivo editing permanent?
Yes, when using nucleases like Cas9 for knockout or knock-in, the DNA changes are permanent. For transient effects, we offer in vivo RNA editing or epigenetic modulation.
4. What delivery method is best for my project?
This depends on the target tissue. AAV is often preferred for long-term expression in post-mitotic cells, while LNPs are highly effective for hepatic or pulmonary targeting.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.